EGFR and lung adenocarcinoma: It has been reported that patients with EGFR-mutant lung adenocarcinoma are more likely to develop brain metastases (39.2% vs. 28.2%; P = 0.038) and meningeal metastases (9.4% vs. 1.7%; P < 0.01) than wild-type patients [34, 35].